Skip to main content
Contact Us
Sign Up
Subscriber Sign In
navigation
サイト内検索
COVID-19
COVID-19 Update
Evaluate Vantage COVID-19 Report
COVID-19 Stories from Evaluate Vantage
Evaluate’s Business Continuity Plan
What We Do
Commercial Intelligence
Products
Evaluate Pharma
Evaluate Epi
Japan Drug Forecasts
Europe Drug Forecasts
Evaluate Custom Solutions
Evaluate Vantage
News
Analysis
Policy & Pricing
Data Insights
Events
Medtech
Therapy Areas
Editorial Team
About Evaluate Vantage
Evaluate for Biotech
How We Can Help You
Pharma and Biotech
Medtech
Financial Services
Management Consultancies
Service Providers
Customer Testimonials
Thought Leadership
About Us
Press Releases
Media Coverage
Executive Team
Vision & History
Careers
Current Vacancies
Contact Us
Sign Up for Evaluate Vantage
Subscriber Sign In
Search
Open configuration options
Search
Vantage
Covid-19
Covid-19 Coverage
Evaluate Vantage COVID-19 Report
News
Snippets
Deals
Trial results
Patents and litigation
Corporate strategy
Analysis
Interviews
Spotlight
Vantage points
Vantage views
Data Insights
M&A
IPO
NME approvals
Quarterly shareprice performance
Venture financing
Vantage data points
Other data
Events
Company events
Conferences
Upcoming events
Medtech
Therapy Areas
About
Editorial team
Sepracor
September 03, 2012
Dainippon takes aim at Spiriva with Elevation buy
January 18, 2011
Big pharma continues M&A spending spree in 2010
October 01, 2010
Novo leads big pharma recovery in third quarter as Roche tumbles
July 01, 2010
Big pharma continues to struggle in first half, Indian generics consolidate gains
May 04, 2010
Dainippon receives an unwelcome knock back to Stedesa
April 09, 2010
Event – Dainippon’s Stedesa PDUFA unlikely to cause ripples in epilepsy market
April 01, 2010
Modest big cap winners and losers in first quarter 2010
March 19, 2010
Somaxon wins approval for Silenor and hunt for partner begins
March 05, 2010
Event - Somaxon facing dream or nightmare PDUFA decision
February 08, 2010
Event - Milestones from Exalgo approval will boost CombinatoRx's fortunes
November 26, 2009
Event - Somaxon awaiting decision that could wake it from slumber
Load More
We use cookies on this website. By using this site, you agree that we may store and access cookies on your device.
Find out more.
OK
Independent, data-driven daily news and analysis on pharma, biotech and medtech.
Sign up
Latest Reports
February 11, 2021
Evaluate Vantage Pharma, Biotech & Medtech 2020 in Review
December 10, 2020
Evaluate Vantage 2021 Preview
Editor's Picks
February 10, 2021
2020 wins top of the froths for biotech stocks
October 04, 2018
Biotech flotations remain in high demand
February 04, 2021
Glaxo’s growth problem
January 27, 2021
Go or no go? Oncology decisions ahead for the FDA
February 05, 2021
Pfizer reveals its PD-1 secret
